中文版 | English
   
   
   
 
 
 

We have broad based research efforts spanning across a number of therapeutic areas.
Eagle Sky PharmaTech is currently pursuing research programs in the following principal areas: cardiovascular and diabetes. In all of these programs, we have identified targets and compounds with demonstrated in vitro and, in some cases, in vivo activity.

Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates.

Eagle Sky PharmaTech is conducting clinical and preclinical studies in its core focus areas, which include the following:
· 胆固醇异常
  ESP-8509 recently completed 近期已经完成先导药物的筛选及化学合成。

· Renin inhibitors 肾素抑制剂
  ESP-9085 recently completed target identification and design. 近期已完成了药物靶点的识别,先导药物的筛选及化学合成及设计.

·DPPIV inhibitors 二肽基肽酶抑制剂
 ESP-8012 completed target identification, screening, lead modification, SAR, in-vitro studies.
 Applied China and US patent.
 ESP-8012 完成了药物靶点的识别,先导化合物的筛选及修饰,体外实验的安全分析报告。
 In addition to the areas noted above, Eagle Sky PharmaTech is continuing to explore the human genome to identify new therapeutic opportunities.
 除了上述所述领域,我公司还在继续探究人体基因组,以发现出新的治疗途径和机会。


     
2009-2015 BEIJING EAGLE SKY PHARMATECH CO., LTD  |  Tel: 86-10-59799429 Fax: 86-10-58043698 Mobilephone: 86-13911359480
Address: Rm 323 , Building 3, Yard A, No. 4, Yongding Rd Jia , Haidian District, Beijing 100039, China
Web: www.eagleskypharmatech.com  |  E-mail: Contact@EagleSkyPharmatech.com  |  marketing@EagleSkyPharmatech.com  |  sales@eagleskypharmatech.com

 京ICP备09110018号